- TRADE NAME: Fotivda (Aveo Oncology)
- INDICATIONS: Treatment of relapsed or refractory advanced renal cell carcinoma following two or more prior systemic therapies.
- CLASS: Kinase inhibitor, Tyrosine kinase inhibitor
- HALF-LIFE: 111 hours
- FDA APPROVAL DATE: 03/10/2021
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
CYP3A inducers - PREGNANCY: Tivozanib may cause fetal harm; contraception is advised.
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 03/14/2024
